These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 21869539)

  • 1. Effects of miglitol in combination with intensive insulin therapy on blood glucose control with special reference to incretin responses in type 1 diabetes mellitus.
    Nagai E; Katsuno T; Miyagawa J; Konishi K; Miuchi M; Ochi F; Kusunoki Y; Tokuda M; Murai K; Hamaguchi T; Namba M
    Endocr J; 2011; 58(10):869-77. PubMed ID: 21869539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
    Kishimoto M; Noda M
    Cardiovasc Diabetol; 2011 Dec; 10():115. PubMed ID: 22189184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men.
    Aoki K; Masuda K; Miyazaki T; Togashi Y; Terauchi Y
    Endocr J; 2010; 57(8):667-72. PubMed ID: 20519806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cotreatment with the α-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients.
    Imai C; Saito M; Mochizuki K; Fuchigami M; Goda T; Osonoi T
    Metabolism; 2014 Jun; 63(6):746-53. PubMed ID: 24559582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of pre-meal versus post-meal administration of miglitol on plasma glucagon-like peptide-1 and glucosedependent insulinotropic polypeptide levels in healthy men.
    Aoki K; Miyazaki T; Nagakura J; Orime K; Togashi Y; Terauchi Y
    Endocr J; 2010; 57(8):673-7. PubMed ID: 20519807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Add-on therapy with anagliptin in Japanese patients with type-2 diabetes mellitus treated with metformin and miglitol can maintain higher concentrations of biologically active GLP-1/total GIP and a lower concentration of leptin.
    Osonoi T; Saito M; Hariya N; Goto M; Mochizuki K
    Peptides; 2016 Dec; 86():118-125. PubMed ID: 27780736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
    Tsuchimochi W; Ueno H; Yamashita E; Tsubouchi C; Sakoda H; Nakamura S; Nakazato M
    Endocr J; 2015; 62(1):13-20. PubMed ID: 25252844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients.
    Narita T; Yokoyama H; Yamashita R; Sato T; Hosoba M; Morii T; Fujita H; Tsukiyama K; Yamada Y
    Diabetes Obes Metab; 2012 Mar; 14(3):283-7. PubMed ID: 22051162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
    Aoki K; Kamiyama H; Yoshimura K; Shibuya M; Masuda K; Terauchi Y
    Acta Diabetol; 2012 Jun; 49(3):225-30. PubMed ID: 21898126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of miglitol as an add-on to bolus insulin on postprandial glycemic excursions in type 2 diabetes patients assessed by continuous glucose monitoring.
    Matsuura K; Mori Y; Nakamura A; Yokoyama J; Utsunomiya K
    Diabetes Technol Ther; 2012 May; 14(5):423-9. PubMed ID: 22316114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
    Lee A; Patrick P; Wishart J; Horowitz M; Morley JE
    Diabetes Obes Metab; 2002 Sep; 4(5):329-35. PubMed ID: 12190996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH) -.
    Hiki M; Shimada K; Kiyanagi T; Fukao K; Hirose K; Ohsaka H; Fukushima Y; Kume A; Matsumori R; Sumiyoshi K; Miyazaki T; Ohmura H; Kurata T; Miida T; Daida H
    Circ J; 2010 Jul; 74(7):1471-8. PubMed ID: 20519875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes.
    Otsuka Y; Yamaguchi S; Furukawa A; Kosuda M; Nakazaki M; Ishihara H
    Endocr J; 2015; 62(2):133-43. PubMed ID: 25328079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes.
    Christensen M; Calanna S; Sparre-Ulrich AH; Kristensen PL; Rosenkilde MM; Faber J; Purrello F; van Hall G; Holst JJ; Vilsbøll T; Knop FK
    Diabetes; 2015 Jan; 64(1):72-8. PubMed ID: 25053587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy.
    Tanaka S; Suzuki K; Aoki C; Niitani M; Kato K; Tomotsune T; Aso Y
    Diabetes Technol Ther; 2014 Dec; 16(12):840-5. PubMed ID: 25144424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of miglitol, sitagliptin, and initial combination therapy with both on plasma incretin responses to a mixed meal and visceral fat in over-weight Japanese patients with type 2 diabetes. "the MASTER randomized, controlled trial".
    Mikada A; Narita T; Yokoyama H; Yamashita R; Horikawa Y; Tsukiyama K; Yamada Y
    Diabetes Res Clin Pract; 2014 Dec; 106(3):538-47. PubMed ID: 25451890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic liraglutide therapy induces an enhanced endogenous glucagon-like peptide-1 secretory response in early type 2 diabetes.
    Kramer CK; Zinman B; Choi H; Connelly PW; Retnakaran R
    Diabetes Obes Metab; 2017 May; 19(5):744-748. PubMed ID: 28181363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant use of miglitol and mitiglinide as initial combination therapy in type 2 diabetes mellitus.
    Tatsumi F; Hashiramoto M; Hirukawa H; Kimura T; Shimoda M; Tawaramoto K; Kanda-Kimura Y; Anno T; Kawasaki F; Mune T; Matsuki M; Kaku K
    Diabetes Res Clin Pract; 2013 Jul; 101(1):35-44. PubMed ID: 23711593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus.
    Mitrakou A; Tountas N; Raptis AE; Bauer RJ; Schulz H; Raptis SA
    Diabet Med; 1998 Aug; 15(8):657-60. PubMed ID: 9702468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus.
    Stephens JW; Bodvarsdottir TB; Wareham K; Prior SL; Bracken RM; Lowe GD; Rumley A; Dunseath G; Luzio S; Deacon CF; Holst JJ; Bain SC
    Diabetes Res Clin Pract; 2011 Nov; 94(2):199-206. PubMed ID: 21835486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.